
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Individualised Management of Reflux-Like Symptoms—Strategies Beyond Acid Suppression</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Individualised Management of Reflux-Like Symptoms—Strategies Beyond Acid Suppression</strong></summary>
            <div>
                <ul><li>Review article published in Alimentary Pharmacology &amp; Therapeutics, 2025.</li><li>Authors: Peter J. Kahrilas, Laurie Keefer, Rena Yadlapati, et al.</li><li>Addresses the complexities of reflux-like symptom pathophysiology and management strategies beyond acid reflux.</li></ul>
                
        <details>
            <summary><strong>Introduction</strong></summary>
            <div>
                <ul><li>Reflux-like symptoms are frequently treated with PPIs, often long-term &amp; at high doses.</li><li>Symptoms are often conflated with reflux oesophagitis, assuming similar responsiveness to acid suppression.</li><li>However, many patients report persistent symptoms despite optimized PPI therapy.</li></ul>
                
        <details>
            <summary><strong>Problem</strong></summary>
            <div>
                <ul><li>Differential clinical responsiveness between reflux oesophagitis and persistent reflux-like symptoms suggests differing pathophysiology.</li><li>This calls into question the shared management strategy.</li></ul>
                
        <details>
            <summary><strong>Aim</strong></summary>
            <div>
                <ul><li>Examine persistently symptomatic patients with non-erosive disease from a primary care/generalist perspective.</li><li>Consider both acid and non-acid targeted interventions based on individual clinical presentation and circumstances.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Methods</strong></summary>
            <div>
                <ul><li>Panel of ten expert clinicians (primary care, gastroenterology, psychology) held online meetings.</li><li>Shared perspectives on pathophysiology and management of reflux-like symptoms when PPIs are ineffective or provide partial relief.</li><li>Focus: Enhance care through personalized strategies from a primary care/generalist perspective.</li></ul>
                
        <details>
            <summary><strong>Process</strong></summary>
            <div>
                <ul><li>Key themes for exploration: underlying contributors of reflux-like symptoms/non-acid-mediated symptoms &amp; alternative (non-acid suppressive) management strategies.</li><li>Members reviewed topics, presented findings, and identified content gaps.</li><li>Output: Examines complexities of reflux-like symptom pathophysiology and management strategies.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pathophysiology</strong></summary>
            <div>
                <ul><li>Understanding the distinct pathophysiologies is crucial for effective management.</li></ul>
                
        <details>
            <summary><strong>Reflux Oesophagitis</strong></summary>
            <div>
                <ul><li>Characterized by endoscopically visible mucosal breaks in the distal oesophagus (Los Angeles Classification: mild A, B; severe C, D).</li><li>Pathophysiology: Incompetence of anti-reflux barrier @ oesophagogastric junction -&gt; hypotensive LES, hiatal hernia -&gt; excessive acid reflux &amp; poor oesophageal clearance.</li><li>Results in increased distal oesophageal acid exposure -&gt; inflammation &amp; mucosal erosions.</li></ul>
                
        <details>
            <summary><strong>Treatment &amp; Management</strong></summary>
            <div>
                <ul><li>Can almost uniformly be healed with potent antisecretory therapy (PPIs or PCABs).</li><li>Healing rates parallel antisecretory potency.</li><li>Irreversible physiological defects (esp. severe oesophagitis) mandate maintenance antisecretory therapy or alternative strategies (weight loss, surgery).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>&#x27;Typical&#x27; Reflux-Like Symptoms</strong></summary>
            <div>
                <ul><li>Montreal Consensus: Typical oesophageal symptoms = heartburn, chest pain, regurgitation.</li><li>Most individuals w/ typical symptoms do NOT have reflux (erosive) oesophagitis -&gt; NERD (non-erosive reflux disease).</li><li>Physiological testing (pH-metry or pH-impedance) reveals heterogeneity.</li></ul>
                
        <details>
            <summary><strong>NERD Subtypes</strong></summary>
            <div>
                <ul><li>True NERD: Abnormal oesophageal acid exposure.</li><li>Reflux hypersensitivity: Normal oesophageal acid exposure, significant correlation between symptoms and reflux events.</li><li>Functional heartburn: Normal oesophageal acid exposure, no significant correlation between symptoms and reflux events.</li></ul>
                
        <details>
            <summary><strong>Problems with Classifications</strong></summary>
            <div>
                <ul><li>Poor correlation between defining symptoms and reflux events; most reflux events are asymptomatic, most symptoms not temporally linked to reflux.</li><li>Disconnect between patient-reported symptom severity and physiological abnormality (oesophageal pH-metry).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Explanation</strong></summary>
            <div>
                <ul><li>Complex process of oesophageal event perception depends on peripheral and central neurologic processes.</li><li>Psychological stressors, cognitive-affective factors, and aberrant coping behaviors are important modulators of symptom experience.</li><li>Neural plasticity leads to hypersensitivity (perception of stimuli not normally perceived).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gut Microbiome Impact</strong></summary>
            <div>
                <ul><li>Gut microbiome (shaped by environment, life experiences, social factors) may impact visceral sensitivity and CNS processing.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Oesophageal Hypervigilance and Anxiety Scale (EHAS)</strong></summary>
            <div>
                <ul><li>Quantifies oesophagus-focused anxiety and symptom vigilance.</li><li>15-item questionnaire, 5-point Likert scale (0-60).</li><li>EHAS score correlates with symptom severity (GERDQ) regardless of NERD subtype (true NERD, reflux hypersensitivity, functional heartburn).</li><li>Shorter 7-item version (EHAS-7) performs as well.</li></ul>
                
        <details>
            <summary><strong>Study Example</strong></summary>
            <div>
                <ul><li>Study of 105 patients w/ reflux-like symptoms (no oesophagitis): EHAS score correlated w/ symptom severity, regardless of classification by pH-impedance testing.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Psychosocial Factors</strong></summary>
            <div>
                <ul><li>Detailed evaluation of 393 &#x27;PPI-refractory&#x27; patients w/ pH-impedance monitoring &amp; psychometric testing.</li><li>Machine-learning model (88% variance in symptom severity) showed psychological variables were most important.</li><li>Top variables: depressive symptoms (0.210), illness behaviour (0.165), PTSD symptoms (0.128), GI-specific anxiety (0.117), pain catastrophizing (0.114).</li><li>Reflux-related variables had lower predictive worth (total 0.109).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Psychosocial Impact Study</strong></summary>
            <div>
                <ul><li>Study of 123 patients w/ abnormal acid exposure &amp; 116 w/ normal acid exposure but positive symptom correlation.</li><li>Oesophageal hypervigilance was persistent across patients, irrespective of pH-metry results, and significantly predicted symptom severity.</li><li>Psychosocial factors are important across the entire spectrum of GERD, including reflux oesophagitis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Disorders of Gut-Brain Interaction (DGBIs)</strong></summary>
            <div>
                <ul><li>Psychological comorbidities and visceral hypersensitivity play a dominant role in symptom perception.</li><li>DGBIs (functional heartburn, dyspepsia, IBS) commonly overlap and coexist with somatic symptoms (headache, backache, insomnia, fibromyalgia, dizziness).</li><li>UK study: DGBIs affect 1 in 3 adults, sparsely recognised/taught in medical education.</li></ul>
                
        <details>
            <summary><strong>Patient Adaptation</strong></summary>
            <div>
                <ul><li>Patient&#x27;s adaptation responses influence symptom experience.</li><li>Rationalizing symptoms -&gt; better coping.</li><li>Flight-or-fight, fear, stress response -&gt; impaired QoL.</li><li>Perception of symptoms as threatening -&gt; avoidance behavior -&gt; reinforcement of fear &amp; restricted life activities.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Oesophageal Hypervigilance</strong></summary>
            <div>
                <ul><li>Behavioral reaction: increased attention to oesophageal symptoms &amp; settings -&gt; &#x27;expect&#x27; symptoms &amp;/or engage in maladaptive coping behaviors to avoid symptoms.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>&#x27;Atypical&#x27; Reflux Symptoms</strong></summary>
            <div>
                <ul><li>Proposed &#x27;atypical&#x27; or extra-oesophageal GERD syndromes: laryngitis, pharyngitis, post-nasal drip, otitis, asthma.</li><li>Patients rarely have reflux oesophagitis on endoscopy -&gt; establishing causative role of reflux is problematic.</li><li>Oesophageal pH-metry or pH-impedance metry are mainstays of evaluation, but interpretation lacks consensus.</li></ul>
                
        <details>
            <summary><strong>Challenges</strong></summary>
            <div>
                <ul><li>Examples of reflux leading to extra-oesophageal syndromes exist, but establishing reflux as a dominant contributor in clinical setting remains problematic.</li><li>Psychosocial factors on symptom burden have received inadequate attention.</li><li>Laryngeal symptoms study: elevated hypervigilance &amp; anxiety (EHAS) in those w/ &amp; w/o abnormal pH-metry.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Heterogeneity</strong></summary>
            <div>
                <ul><li>Substantial heterogeneity exists, with some phenotypes driven by abnormal reflux physiology and some by hypersensitivity and behavioural factors.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>General Principles</strong></summary>
            <div>
                <ul><li>Uncommon for reflux to be dominant cause of extra-oesophageal syndromes in patients without typical oesophageal symptoms.</li><li>Even when reflux is involved, it is usually one of multiple contributors and often not the dominant one.</li><li>Diagnostics (pH-metry or pH-impedance metry) are more helpful in ruling out GERD than ruling it in.</li><li>Strong tendency to over-treat these patients with PPIs.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Overlapping Gastrointestinal Symptoms</strong></summary>
            <div>
                <ul><li>Dyspeptic symptoms frequently overlap with reflux-like symptoms and are often present in PPI &#x27;non-responders&#x27;.</li><li>Functional heartburn has more in common with functional dyspepsia than reflux disease (more postprandial fullness, bloating, early satiety, nausea).</li><li>IBS overlaps more frequently with functional heartburn than true NERD and reflux hypersensitivity.</li></ul>
                
        <details>
            <summary><strong>Clinical Implications</strong></summary>
            <div>
                <ul><li>Question patients to differentiate between dyspeptic and reflux-like symptoms.</li><li>Avoid medical jargon; use easy-to-understand tools (pictograms) to simplify communication.</li><li>H. pylori testing is important in dyspepsia management but generally unnecessary in patients with only typical reflux-like symptoms.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Potential Lifestyle Contributors to Reflux-Like Symptoms</strong></summary>
            <div>
                <ul><li>Lifestyle factors can significantly influence reflux symptoms.</li></ul>
                
        <details>
            <summary><strong>Dietary Habits</strong></summary>
            <div>
                <ul><li>Poor dietary habits (eating past satiety, eating close to bedtime) are associated with gastro-oesophageal reflux.</li><li>Large meals cause gastric distention, promote acid secretion, trigger transient LES relaxations, and make reflux from the postprandial acid pocket more likely.</li><li>Dietary triggers vary widely among patients.</li></ul>
                
        <details>
            <summary><strong>Common Dietary Triggers</strong></summary>
            <div>
                <ul><li>Coffee, alcohol, chocolate, diets rich in fat or carbohydrate, fried foods, highly processed foods (high sugar, salt, saturated fats).</li><li>Carbonated beverages increase heartburn risk during sleep.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Weight Gain, Obesity and Hiatal Hernia</strong></summary>
            <div>
                <ul><li>Reflux-like symptoms increase progressively with BMI increases.</li><li>Obesity is an important risk factor for reflux complications (oesophagitis, Barrett&#x27;s, adenocarcinoma).</li><li>Hiatal hernia and increased intra-abdominal pressure are important physiological risk factors for reflux and are linked to obesity.</li></ul>
                
        <details>
            <summary><strong>Hiatal Hernia</strong></summary>
            <div>
                <ul><li>Spectrum of disruption of the diaphragmatic hiatus culminating in hiatal hernia is age-related and is the likely dominant pathophysiological factor linking advancing age to reflux.</li><li>Excessive abdominal straining (weight training) can also cause hiatal hernia.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Individualised Management Strategies</strong></summary>
            <div>
                <ul><li>Personalized strategies are key to effective management.</li></ul>
                
        <details>
            <summary><strong>Expectation Setting and Counselling</strong></summary>
            <div>
                <ul><li>Reflux-like symptoms have a multifactorial pathophysiology and wax and wane over time.</li><li>Decision to continue PPI long-term will be individualised, based on symptomatic benefit and patient preference.</li><li>Management should be patient-centred, reflective of physiological, behavioural and dietary factors.</li></ul>
                
        <details>
            <summary><strong>Addressing Misconceptions</strong></summary>
            <div>
                <ul><li>Complex pathophysiology is often oversimplified as excessive acid exposure.</li><li>&#x27;PPI failure&#x27; may be more a problem of unrealistic expectations than PPI efficacy.</li><li>Over-the-counter products and direct-to-consumer advertising can boost expectations.</li></ul>
                
        <details>
            <summary><strong>Patient Fears</strong></summary>
            <div>
                <ul><li>Unmet expectations can generate fear about alternative reasons for refractory symptoms (cancer, heart disease).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Approach</strong></summary>
            <div>
                <ul><li>Identify specific contributing factors: understand patient&#x27;s circumstances, perceptions, symptom type, severity, comorbidities, treatment history, alarm features.</li><li>Counsel patients on multi-factorial aetiology, including the gut-brain connection.</li><li>Explain that a single intervention is unlikely to be a perfect solution.</li></ul>
                
        <details>
            <summary><strong>Gut-Brain Axis Explanation</strong></summary>
            <div>
                <ul><li>Explain the gut-brain axis in patient-friendly language as a two-way communication pathway.</li><li>Certain thoughts, feelings, and behaviours can increase the perception of and response to symptoms in the GI tract.</li><li>Reassure patients that symptoms are not &#x27;all in the mind&#x27;.</li></ul>
                
        <details>
            <summary><strong>Treatment Aims</strong></summary>
            <div>
                <ul><li>Clinicians should reassure patients that the sensory pathways that are triggering symptoms can be modified.</li><li>Treatment aims to achieve steady and continued improvement rather than immediate resolution.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Doctor-Patient Relationship</strong></summary>
            <div>
                <ul><li>Key to holistic management based on patient experience.</li><li>Active listening, compassion, rapport building to elicit information (life stressors, anxiety, trauma).</li><li>PRO tools (EHAS, GERDQ, GIS, QOLRAD) can make consultations more interactive, effective, and efficient.</li></ul>
                
        <details>
            <summary><strong>Reassurance</strong></summary>
            <div>
                <ul><li>Reassure patients that the risk of developing oesophageal cancer is extremely low.</li><li>UK National Endoscopy Database: low diagnostic yield from gastroscopy for symptom evaluation (0.2-0.3% positive predictive value for cancer in reflux/dyspepsia).</li><li>Investigation often required for reassurance.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diet and Lifestyle Changes</strong></summary>
            <div>
                <ul><li>Key element of care for all patients with reflux-like symptoms.</li><li>Rigorous evidence from RCTs is scarce, but the concept that dietary and lifestyle changes can lower the risk of reflux-related symptoms is well established.</li><li>Relevant contributors are highly individualised.</li></ul>
                
        <details>
            <summary><strong>Recommendations</strong></summary>
            <div>
                <ul><li>Avoid high-fat foods and potential dietary triggers (citrus, tomatoes, spiced/fried foods, chocolate, alcohol, coffee, carbonated drinks), overeating, and recumbency after meals.</li><li>Simple strategies: smaller plates, cut-off time for last meal (3-h interval before bedtime), raising head of bed.</li></ul>
                
        <details>
            <summary><strong>Mindful Eating</strong></summary>
            <div>
                <ul><li>Lessons from Japanese practice of &#x27;mindful eating&#x27;: heightened awareness of satiety cues by paying attention to flavours, textures, and chewing.</li><li>Pre-meal mantra &#x27;hara hachi bu&#x27; or “eat until you are 80% full”.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Weight Management</strong></summary>
            <div>
                <ul><li>Recommended for overweight/obese patients and those with recent weight gain.</li><li>Weight loss reduces symptoms dose-dependently and increases the chance of treatment success with acid-reducing/neutralising medicines.</li></ul>
                
        <details>
            <summary><strong>Comparative Study</strong></summary>
            <div>
                <ul><li>Symptomatic overweight patients with reflux oesophagitis: PPI + tailored dietetic/aerobic exercise program -&gt; greater symptom improvement &amp; &gt;50% able to discontinue PPI vs. no patients on PPI alone.</li></ul>
                
        <details>
            <summary><strong>Interventions</strong></summary>
            <div>
                <ul><li>Specific weight management intervention will depend on local services.</li><li>GLP-1RA may be available to support weight loss as an adjunct to calorie-restricted diet and exercise.</li><li>Specific clinical data for these drugs for overweight patients with reflux-like symptoms is not yet available.</li></ul>
                
        <details>
            <summary><strong>GLP-1RA Risk</strong></summary>
            <div>
                <ul><li>Some short-acting GLP-1RAs may increase the risk of oesophagitis and Barrett&#x27;s oesophagus (with and without dysplasia) in patients with type 2 diabetes.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Atypical (Laryngopharyngeal) Symptoms</strong></summary>
            <div>
                <ul><li>PPI treatment is a common approach, but evidence from RCTs demonstrates little, if any, benefit over placebo.</li><li>Disconnect between objective findings and symptom severity.</li></ul>
                
        <details>
            <summary><strong>Anti-Reflux Surgery Study</strong></summary>
            <div>
                <ul><li>Patients with &#x27;PPI-refractory&#x27; laryngopharyngeal symptoms undergoing anti-reflux surgery: laryngeal signs improved in 80%, but only 10% showed symptomatic improvement.</li></ul>
                
        <details>
            <summary><strong>Paradigm Shift</strong></summary>
            <div>
                <ul><li>Moving toward a phenotype-driven, personalised approach where the role of psychosocial factors on symptom perception and burden is acknowledged.</li><li>Vehicle of chronicity is laryngeal hypersensitivity amplified by anxiety, hypervigilance, and learned detrimental behaviours (throat clearing, chronic cough).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Laryngeal Cognitive-Affective Tool (LCAT)</strong></summary>
            <div>
                <ul><li>15-item questionnaire validated for measurement of laryngeal hypervigilance and symptom-specific anxiety in patients with chronic laryngeal symptoms.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Psychological Interventions</strong></summary>
            <div>
                <ul><li>Brain-gut behaviour therapies (BGBT) may be beneficial in patients who identify a link between stress and symptoms, those with difficulty coping, and those who exhibit avoidance behaviours.</li><li>BGBTs reduce both reflux symptom severity and psychological symptoms (GI-specific anxiety) -&gt; improved QoL.</li><li>EHAS tool can gauge levels of symptom-associated anxiety and hypervigilance.</li></ul>
                
        <details>
            <summary><strong>Candidate Selection</strong></summary>
            <div>
                <ul><li>Good candidates: accept and show interest in the gut-brain connection, acknowledge that coping could be improved, and are willing to invest time in behaviour change.</li><li>BGBT techniques may be combined with pharmacological approaches (tricyclic antidepressants, SSRIs/SNRIs).</li></ul>
                
        <details>
            <summary><strong>BGBT Techniques</strong></summary>
            <div>
                <ul><li>Nurse-led GI self-management skills training, GI-focused CBT, gut-directed hypnotherapy, mindfulness-based interventions.</li><li>Oesophageal-directed hypnotherapy study: significant improvement in heartburn impact (QOLRAD, p = 0.01), visceral anxiety (p = 0.01), and emotional QoL (p = 0.05).</li></ul>
                
        <details>
            <summary><strong>Individualized Therapy</strong></summary>
            <div>
                <ul><li>Combination of techniques can be used to individualise therapy to a patient&#x27;s specific needs or therapeutic targets (avoidance behaviour, visceral hypersensitivity, trait anxiety).</li><li>Primary care is ideally placed to implement nurse-led self-management skills training.</li><li>Stress management and relaxation techniques may be key components of self-management programmes.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Atypical Symptoms</strong></summary>
            <div>
                <ul><li>BGBT may also be relevant for patients with chronic atypical symptoms who have developed laryngeal-specific anxiety and hypervigilance.</li><li>Laryngeal recalibration therapy (cognitive behavioural element): 85% symptomatic response, whether or not they had proven underlying reflux disease.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diaphragmatic Breathing</strong></summary>
            <div>
                <ul><li>May be effective for reducing reflux-like symptoms.</li><li>Activates parasympathetic nervous system, increases LES pressure and crural diaphragm tension, and may be especially useful for patients with regurgitation.</li><li>Can also help relaxation by increasing vagal tone, which is disrupted in DGBIs.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>On-Demand Symptom Control Measures</strong></summary>
            <div>
                <ul><li>Growing resistance to maintenance PPI therapy has led to PPI deprescribing initiatives.</li><li>Alternative to continuous maintenance treatment: on-demand symptom control strategy.</li><li>Antacid or alginate-antacid products are useful for postprandial acid reflux and regurgitation and for those with a hiatal hernia.</li></ul>
                
        <details>
            <summary><strong>Alginate-Antacid Mechanism</strong></summary>
            <div>
                <ul><li>Forms a viscous pH-neutral raft on contact with the postprandial acid pocket.</li><li>Reduces the proximal migration of acid reflux episodes and displaces the acid pocket below the diaphragm in patients with a hiatal hernia.</li><li>Meta-analyses show efficacy for symptom control versus placebo and non-inferiority to some PPIs.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Mucosal Protection</strong></summary>
            <div>
                <ul><li>Alginates and other bioadhesive treatments that coat the oesophagus may reduce symptoms through protecting the mucosa.</li><li>Hyaluronic acid–chondroitin sulphate-based bioadhesive formulation has demonstrated superior reduction in reflux-like symptoms compared with placebo in patients with NERD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Adjunct Therapy</strong></summary>
            <div>
                <ul><li>On-demand therapy can also be useful as an alternative to dose escalation in patients being maintained on acid suppressive therapy.</li><li>Topical mucosal preparations containing alginate or protective bioadhesive agents added to a PPI in patients with residual symptoms show benefit.</li><li>Alginate preparation added to a PPI significantly reduced the number of nights with reflux-like symptoms compared with a PPI alone.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Summary</strong></summary>
            <div>
                <ul><li>PPIs are extremely effective for healing reflux oesophagitis, but less so for resolving persistent reflux-like symptoms and even less for atypical reflux symptoms.</li><li>Discrepancy is related to differences in pathophysiological determinants.</li><li>Anatomical/physiological degradation of the anti-reflux barrier dominates in reflux oesophagitis; cognitive-affective and behavioural processes increase symptom burden.</li></ul>
                
        <details>
            <summary><strong>Key Factors</strong></summary>
            <div>
                <ul><li>Hypersensitivity, hypervigilance, and anxiety are important contributors that correlate closely with symptom severity and persistence.</li><li>Management strategies should be individualised, beginning with expectation setting and counselling.</li></ul>
                
        <details>
            <summary><strong>Effective Management</strong></summary>
            <div>
                <ul><li>Utilise behaviour modification (diet/lifestyle changes, weight control), education regarding brain-gut interactions, psychological interventions, and on-demand symptom control measures as either a substitute or adjunct.</li><li>Acid suppression is just one of several interventions that can be utilised as part of an individualised approach to care.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
